Medication info
Sitamet XR Sustained-release Tablet 50/500 mg (Sitagliptin, Metformin)

Sitamet XR Sustained-release Tablet 50/500 mg (Sitagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tabletSitagliptin Phosphate Hydrate›64.25mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Bright blue, double-convex, oval-shaped, sustained-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201505031 · Approved 2015.07.23 · Insurance code 643507370

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Determine the dose based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. Take this medicine with a meal once daily, preferably in the evening, and increase the dose gradually. For this 100/1000 mg extended-release tablet, take 1 tablet once daily. Patients taking this 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. Patients not currently receiving metformin: The initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg. For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the current metformin dose. Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start with their current doses of sitagliptin and metformin. Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this 50/1000 mg extended-release tablet once daily. Patients who do not achieve adequate glycemic control with concomitant metformin and sulfonylurea, metformin and insulin, or metformin and thiazolidinedione therapy: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis: Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this medicine immediately.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps improve blood glucose control in patients with type 2 diabetes by combining sitagliptin and metformin. When administered alongside dietary control and exercise therapy, it is effective in managing blood glucose levels, thereby contributing to more stable blood glucose maintenance. Therefore, this medication is used for the treatment of type 2 diabetes.

How to take

Adult dose

Determine the dose based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. Take this medicine with a meal once daily, preferably in the evening, and increase the dose gradually. For this 100/1000 mg extended-release tablet, take 1 tablet once daily. Patients taking this 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. Patients not currently receiving metformin: The initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg. For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the current metformin dose. Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start with their current doses of sitagliptin and metformin. Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this 50/1000 mg extended-release tablet once daily. Patients who do not achieve adequate glycemic control with concomitant metformin and sulfonylurea, metformin and insulin, or metformin and thiazolidinedione therapy: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis: Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this medicine immediately.

Precautions

This medication contains sitagliptin and metformin and is primarily used for the treatment of type 2 diabetes. During the use of this medication, serious allergic reactions may occur, so if you experience a skin rash, difficulty breathing, or swelling of the face or neck, you should immediately discontinue use and consult a physician. Pancreatitis, an inflammation of the pancreas, may occur rarely, so if you experience symptoms such as abdominal pain, nausea, or vomiting, you must inform medical personnel immediately. Patients with poor kidney function, especially those with moderate to severe renal impairment, should not take this medication, and caution is needed in conditions that may cause a rapid deterioration in kidney function. Patients with severe heart failure, acute myocardial infarction, severe infections, or other unstable physical conditions should also avoid taking this medication. Prior to and after the use of iodine-containing contrast agents for testing, the use of this medication should be temporarily discontinued, and it should be resumed only after confirming normal kidney function. Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this medication. Irregular eating, excessive exercise, or concurrent use with other medications may increase the risk of side effects such as hypoglycemia or lactic acidosis, so caution is necessary. Gastrointestinal side effects such as diarrhea, nausea, vomiting, and abdominal pain may occur with this medication, and if these symptoms persist or worsen, you should consult with medical personnel. Symptoms of hypoglycemia may appear, so especially when taken together with insulin or sulfonylurea drugs, blood glucose levels should be monitored frequently, and appropriate actions should be taken in the event of hypoglycemic symptoms. During treatment with this medication, regular kidney function and hematological tests should be conducted, as vitamin B12 deficiency may occur and periodic testing is required. Patients awaiting surgery should discontinue this medication 48 hours prior to surgery and can resume once kidney function has recovered to normal post-surgery. Excessive alcohol intake increases the risk of lactic acidosis, so alcohol consumption should be avoided during treatment. If symptoms such as sudden difficulty breathing, muscle pain, weakness, or alterations in consciousness occur during the use of this medication, you must inform medical personnel immediately. Elderly patients may have a potential decline in kidney function, making dosage adjustment and regular kidney function monitoring important. In case of overdose, consult medical personnel immediately, and treatment such as hemodialysis may be required if necessary.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 20 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis
  • elevated liver enzymes
  • acute renal failure
  • hypoglycemia
  • peripheral edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. The recommended storage temperature is between 1 and 30 degrees Celsius at room temperature. This helps maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Bright blue, double-convex, oval-shaped, sustained-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.